Sanofi Pasteur buys rights to Pseudomonas aeruginosa antibody candidate
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur has acquired the worldwide rights to KaloBios Pharmaceuticals' "humaneered" antibody fragment for the treatment and prevention of Pseudomonas aeruginosa infections. Financial terms of the deal were not disclosed.